tirzepatide osa study Diabetes & Weight Loss Drug Now Approved for (Obstructive Sleep Apnea) FDA approves tirzepatide to treat

doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review

This means being mindful of not only how much you're drinking but also how you're drinking

This leads to an extended feeling of fullness, which often contributes to a decreased food intake

For GLP-1 users dealing with food sensitivities and restricted eating, this allergen profile is a genuine advantage

This was the big breakthrough